Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
106.3 USD | +0.67% | +0.25% | -3.49% |
29/04 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
26/04 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.49% | 184B | |
-0.49% | 109B | |
-2.39% | 68.37B | |
+4.85% | 51.56B | |
+10.07% | 44.69B | |
+4.37% | 41.49B | |
+3.27% | 26.75B | |
+4.30% | 26.7B | |
+15.38% | 25.68B | |
-0.50% | 24.8B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Abbott Laboratories : Barclays Adjusts Abbott Laboratories' Price Target to $125 From $150, Maintains Overweight Rating